Shijiazhuang Yiling Pharmaceutical Management
Management criteria checks 2/4
Shijiazhuang Yiling Pharmaceutical's CEO is Xiang Jun Wu, appointed in Apr 2013, has a tenure of 11.75 years. directly owns 5.2% of the company’s shares, worth CN¥1.35B. The average tenure of the management team and the board of directors is 11.8 years and 8.1 years respectively.
Key information
Xiang Jun Wu
Chief executive officer
CN¥3.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 11.8yrs |
| CEO ownership | 5.2% |
| Management average tenure | 11.8yrs |
| Board average tenure | 8.1yrs |
Recent management updates
Recent updates
Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has A Pretty Healthy Balance Sheet
Jan 22
Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Business Is Trailing The Industry But Its Shares Aren't
Nov 26Shijiazhuang Yiling Pharmaceutical's (SZSE:002603) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 04Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Using Too Much Debt?
Sep 25Shijiazhuang Yiling Pharmaceutical Co., Ltd.'s (SZSE:002603) Subdued P/S Might Signal An Opportunity
Aug 07Shijiazhuang Yiling Pharmaceutical (SZSE:002603) Has Announced That Its Dividend Will Be Reduced To CN¥0.30
Jul 15Is Shijiazhuang Yiling Pharmaceutical (SZSE:002603) A Risky Investment?
May 26Weak Statutory Earnings May Not Tell The Whole Story For Shijiazhuang Yiling Pharmaceutical (SZSE:002603)
May 05Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SZSE:002603) Analysts Just Cut Their EPS Forecasts Substantially
May 02Should You Be Adding Shijiazhuang Yiling Pharmaceutical (SZSE:002603) To Your Watchlist Today?
Mar 01CEO
Xiang Jun Wu (49 yo)
11.8yrs
Tenure
CN¥3,154,300
Compensation
Mr. Xiang Jun Wu served as Deputy General Manager and Shijiazhuang Yiling Pharmaceutical Co., Ltd. and had been its Marketing Center General manager Since 2005. He is a Director since August 31, 2010 and G...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 11.8yrs | CN¥3.15m | 5.2% CN¥ 1.4b | |
| CFO & Director | 6.8yrs | CN¥1.83m | no data | |
| Deputy GM & Director of Administrative Center | 14yrs | CN¥944.90k | 0.12% CN¥ 31.3m | |
| Executive Deputy Director of the Human Resources Center & Director | no data | CN¥939.10k | 0.017% CN¥ 4.5m | |
| Secretary of the Board & Non-Independent Director | 14.4yrs | CN¥1.83m | 0.59% CN¥ 152.1m | |
| Deputy GM & Non-Independent Director | no data | CN¥2.16m | 0.017% CN¥ 4.4m | |
| Deputy GM & Director of the Supply Center | 1.9yrs | CN¥1.41m | 0.032% CN¥ 8.3m |
11.8yrs
Average Tenure
54yo
Average Age
Experienced Management: 002603's management team is seasoned and experienced (11.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 14.4yrs | CN¥3.15m | 5.2% CN¥ 1.4b | |
| CFO & Director | 6.7yrs | CN¥1.83m | no data | |
| Executive Deputy Director of the Human Resources Center & Director | 5yrs | CN¥939.10k | 0.017% CN¥ 4.5m | |
| Secretary of the Board & Non-Independent Director | 8.1yrs | CN¥1.83m | 0.59% CN¥ 152.1m | |
| Deputy GM & Non-Independent Director | 5yrs | CN¥2.16m | 0.017% CN¥ 4.4m | |
| Chairman of the Supervisory Board | 10.4yrs | no data | 0.074% CN¥ 19.3m | |
| Director | 11.8yrs | CN¥971.80k | 0.037% CN¥ 9.6m | |
| Supervisor | 10.4yrs | no data | 0.00065% CN¥ 169.0k | |
| Supervisor | 14.4yrs | no data | no data | |
| Independent Director | 5yrs | CN¥116.60k | no data | |
| Independent Director | 1.9yrs | CN¥100.00k | no data |
8.1yrs
Average Tenure
54yo
Average Age
Experienced Board: 002603's board of directors are considered experienced (8.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 00:26 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shijiazhuang Yiling Pharmaceutical Co., Ltd. is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Weiying Tu | China International Capital Corporation Limited |
| Diandian Li | China Merchants Securities Co. Ltd. |